FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054694908> ?p ?o ?g. }

• W2054694908 endingPage "C272" @default.
• W2054694908 startingPage "C272" @default.
• W2054694908 abstract "Abstract The oncogenic receptor tyrosine kinases (RTK) AXL and c-Met are over-expressed and constitutively activated in a variety of human cancers. Activation of these receptors contributes to multiple steps in tumor progression, including the epithelial-mesenchymal transition (EMT) by which cancer cells escape to form metastases and frequently develop resistance to a variety of agents, most notably to epidermal growth factor receptor (EGFR) targeted therapies. CEP-40783 is an orally-active, nanomolar potent and highly kinase-selective Type II inhibitor of the AXL and c-Met RTK in drug development. In the current study, five Champions human TumorGraft™ models of NSCLC expressing constitutively activated AXL and/or c-Met were used to determine the anti-tumor efficacy of single agent CEP-40783 compared to paclitaxel and the EGFR inhibitor, erlotinib (Genentech-Roche; OSI Pharmaceuticals). Champions Oncology has developed an innovative platform that utilizes the implantation of primary human tumors in immune-deficient mice in a manner that preserves the biological properties of the original human tumor and results in more rigorous and clinically relevant models for drug discovery. Previous reports have shown the correlation between responsiveness observed in Champions TumorGraft™ models and clinical responses of the patients from which the models were derived. Mice bearing established Champions TumorGrafts™ were treated orally with 10 mg/kg and 30 mg/kg qd of CEP-40783 for 10 to 34 days (until control tumors achieved &gt;1000 mm3 volume) and anti-tumor efficacy and tolerability were evaluated. In 3/5 (60%) of the tumor models, CEP-40783 showed in vivo efficacy, including tumor regressions, significantly superior to that achieved with an optimal regimen of paclitaxel. In 4/4 (100%) of the erlotinib-insensitive tumor models, CEP-40783 demonstrated significant efficacy (66 to 118% TGI) compared to the control group at the 30 mg/kg dose. Additionally, CEP-40783 in combination with erlotinib demonstrated superior anti-tumor efficacy compared to CEP-40783 and erlotinib single agents in the one erlotinib-sensitive model evaluated. CEP-40783 as a single agent and in combination with erlotinib was well tolerated. Retrospective bioinformatics analyses are planned to determine potential signatures of response and resistance to CEP-40783. These results demonstrate that CEP-40783 shows superior efficacy alone and in combination with erlotinib in Champions TumorGraft™ models of NSCLC compared to SOC agents and supports the development of CEP-40783 for the treatment of erlotinib-resistant NSCLC. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C272. Citation Format: Jay A. Friedman, Rodney Donaldson, Sheila Miknyoczki, Mangeng Cheng, Robert Hudkins, Bruce Dorsey, Mark Ator, Thelma Angeles, Bruce Ruggeri, Elizabeth Bruckheimer. Antitumor activity of the dual AXL/c-Met inhibitor CEP-40783 in Champions primary TumorGraft™ models of human non-small cell lung cancer (NSCLC). [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C272." @default.
• W2054694908 created "2016-06-24" @default.
• W2054694908 creator A5020667709 @default.
• W2054694908 creator A5029840953 @default.
• W2054694908 creator A5032621471 @default.
• W2054694908 creator A5054879064 @default.
• W2054694908 creator A5062211526 @default.
• W2054694908 creator A5063125862 @default.
• W2054694908 creator A5066909701 @default.
• W2054694908 creator A5067449660 @default.
• W2054694908 creator A5069322702 @default.
• W2054694908 creator A5080144289 @default.
• W2054694908 date "2013-11-01" @default.
• W2054694908 modified "2023-10-16" @default.
• W2054694908 title "Abstract C272: Antitumor activity of the dual AXL/c-Met inhibitor CEP-40783 in Champions primary TumorGraft™ models of human non-small cell lung cancer (NSCLC)." @default.
• W2054694908 doi "https://doi.org/10.1158/1535-7163.targ-13-c272" @default.
• W2054694908 hasPublicationYear "2013" @default.
• W2054694908 type Work @default.
• W2054694908 sameAs 2054694908 @default.
• W2054694908 citedByCount "2" @default.
• W2054694908 countsByYear W20546949082014 @default.
• W2054694908 crossrefType "journal-article" @default.
• W2054694908 hasAuthorship W2054694908A5020667709 @default.
• W2054694908 hasAuthorship W2054694908A5029840953 @default.
• W2054694908 hasAuthorship W2054694908A5032621471 @default.
• W2054694908 hasAuthorship W2054694908A5054879064 @default.
• W2054694908 hasAuthorship W2054694908A5062211526 @default.
• W2054694908 hasAuthorship W2054694908A5063125862 @default.
• W2054694908 hasAuthorship W2054694908A5066909701 @default.
• W2054694908 hasAuthorship W2054694908A5067449660 @default.
• W2054694908 hasAuthorship W2054694908A5069322702 @default.
• W2054694908 hasAuthorship W2054694908A5080144289 @default.
• W2054694908 hasConcept C101544691 @default.
• W2054694908 hasConcept C121608353 @default.
• W2054694908 hasConcept C126322002 @default.
• W2054694908 hasConcept C143998085 @default.
• W2054694908 hasConcept C157333092 @default.
• W2054694908 hasConcept C170493617 @default.
• W2054694908 hasConcept C2776256026 @default.
• W2054694908 hasConcept C2776996007 @default.
• W2054694908 hasConcept C2777292972 @default.
• W2054694908 hasConcept C2778087573 @default.
• W2054694908 hasConcept C2779256057 @default.
• W2054694908 hasConcept C2779438470 @default.
• W2054694908 hasConcept C2780467284 @default.
• W2054694908 hasConcept C2781064419 @default.
• W2054694908 hasConcept C502942594 @default.
• W2054694908 hasConcept C5364575 @default.
• W2054694908 hasConcept C71924100 @default.
• W2054694908 hasConcept C98274493 @default.
• W2054694908 hasConceptScore W2054694908C101544691 @default.
• W2054694908 hasConceptScore W2054694908C121608353 @default.
• W2054694908 hasConceptScore W2054694908C126322002 @default.
• W2054694908 hasConceptScore W2054694908C143998085 @default.
• W2054694908 hasConceptScore W2054694908C157333092 @default.
• W2054694908 hasConceptScore W2054694908C170493617 @default.
• W2054694908 hasConceptScore W2054694908C2776256026 @default.
• W2054694908 hasConceptScore W2054694908C2776996007 @default.
• W2054694908 hasConceptScore W2054694908C2777292972 @default.
• W2054694908 hasConceptScore W2054694908C2778087573 @default.
• W2054694908 hasConceptScore W2054694908C2779256057 @default.
• W2054694908 hasConceptScore W2054694908C2779438470 @default.
• W2054694908 hasConceptScore W2054694908C2780467284 @default.
• W2054694908 hasConceptScore W2054694908C2781064419 @default.
• W2054694908 hasConceptScore W2054694908C502942594 @default.
• W2054694908 hasConceptScore W2054694908C5364575 @default.
• W2054694908 hasConceptScore W2054694908C71924100 @default.
• W2054694908 hasConceptScore W2054694908C98274493 @default.
• W2054694908 hasIssue "11_Supplement" @default.
• W2054694908 hasLocation W20546949081 @default.
• W2054694908 hasOpenAccess W2054694908 @default.
• W2054694908 hasPrimaryLocation W20546949081 @default.
• W2054694908 hasRelatedWork W1598456512 @default.
• W2054694908 hasRelatedWork W1981976406 @default.
• W2054694908 hasRelatedWork W1990395674 @default.
• W2054694908 hasRelatedWork W2012871610 @default.
• W2054694908 hasRelatedWork W2026488530 @default.
• W2054694908 hasRelatedWork W2044179984 @default.
• W2054694908 hasRelatedWork W2089858549 @default.
• W2054694908 hasRelatedWork W2218316732 @default.
• W2054694908 hasRelatedWork W2417693965 @default.
• W2054694908 hasRelatedWork W2956136764 @default.
• W2054694908 hasVolume "12" @default.
• W2054694908 isParatext "false" @default.
• W2054694908 isRetracted "false" @default.
• W2054694908 magId "2054694908" @default.
• W2054694908 workType "article" @default.